Skip to main content
icon for Eli Lilly licenses Peptron’s SmartDepot by October 7?

Eli Lilly licenses Peptron’s SmartDepot by October 7?

icon for Eli Lilly licenses Peptron’s SmartDepot by October 7?

Eli Lilly licenses Peptron’s SmartDepot by October 7?

13% সম্ভাবনা
Polymarket

$11,264 Vol.

13% সম্ভাবনা
Polymarket

$11,264 Vol.

This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s 2024 agreement with Peptron granted only non-exclusive research rights to evaluate SmartDepot—an ultrasonic spray-dried PLGA microsphere platform for one- to six-month peptide release—without commercial manufacturing or sales rights. Nearly two years later, no binding technology-transfer or licensing deal has been announced. Lilly separately partnered with Camurus in June 2026 for its competing FluidCrystal platform targeting long-acting incretins, while recent clarifications excluded tirzepatide from the Peptron program and the company has pivoted toward oral obesity candidates. With resolution weeks away and no disclosed commercial progress, traders assign 87.5% probability to “No.”

This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.

Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.

Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.

The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
ভলিউম
$11,264
শেষ তারিখ
Oct 7, 2026
মার্কেট ওপেন হয়েছে
May 5, 2026, 8:02 PM ET
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s 2024 agreement with Peptron granted only non-exclusive research rights to evaluate SmartDepot—an ultrasonic spray-dried PLGA microsphere platform for one- to six-month peptide release—without commercial manufacturing or sales rights. Nearly two years later, no binding technology-transfer or licensing deal has been announced. Lilly separately partnered with Camurus in June 2026 for its competing FluidCrystal platform targeting long-acting incretins, while recent clarifications excluded tirzepatide from the Peptron program and the company has pivoted toward oral obesity candidates. With resolution weeks away and no disclosed commercial progress, traders assign 87.5% probability to “No.”

This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.

Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.

Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.

The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
ভলিউম
$11,264
শেষ তারিখ
Oct 7, 2026
মার্কেট ওপেন হয়েছে
May 5, 2026, 8:02 PM ET
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.

বাহ্যিক লিংক থেকে সাবধান।

সচরাচর জিজ্ঞাসা

"Eli Lilly licenses Peptron’s SmartDepot by October 7?" হলো Polymarket-এ একটি প্রেডিকশন মার্কেট যেখানে ট্রেডাররা এই ইভেন্টটি ঘটবে কিনা তার ভিত্তিতে "Yes" বা "No" শেয়ার কেনাবেচা করে। বর্তমান ক্রাউড-সোর্সড সম্ভাবনা "Yes"-এর জন্য 13%। যেমন, "Yes" 13¢-এ মূল্যায়িত হলে, মার্কেট সম্মিলিতভাবে এই ইভেন্টটি ঘটার 13% সম্ভাবনা নির্ধারণ করে। ট্রেডাররা নতুন ডেভেলপমেন্ট ও তথ্যে প্রতিক্রিয়া জানালে এই অডস ক্রমাগত পরিবর্তিত হয়। মার্কেট রেজোলিউশনে সঠিক ফলাফলের শেয়ার প্রতিটি $1-এ রিডিমযোগ্য।

আজ পর্যন্ত, "Eli Lilly licenses Peptron’s SmartDepot by October 7?" মোট $11.3K ট্রেডিং ভলিউম তৈরি করেছে মার্কেট May 5, 2026-এ লঞ্চ হওয়ার পর থেকে। এই স্তরের ট্রেডিং অ্যাক্টিভিটি Polymarket কমিউনিটির শক্তিশালী এনগেজমেন্ট প্রতিফলিত করে এবং নিশ্চিত করতে সাহায্য করে যে বর্তমান অডস মার্কেট অংশগ্রহণকারীদের একটি গভীর পুল দ্বারা অবহিত। আপনি এই পেজে সরাসরি লাইভ মূল্য মুভমেন্ট ট্র্যাক করতে ও যেকোনো ফলাফলে ট্রেড করতে পারেন।

"Eli Lilly licenses Peptron’s SmartDepot by October 7?"-এ ট্রেড করতে, শুধু বেছে নিন আপনি বিশ্বাস করেন উত্তর "Yes" নাকি "No"। প্রতিটি সাইডের একটি বর্তমান দাম আছে যা মার্কেটের ইম্প্লায়েড প্রবাবিলিটি প্রতিফলিত করে। আপনার পরিমাণ লিখুন এবং "Trade" ক্লিক করুন। যদি আপনি "Yes" শেয়ার কেনেন এবং ফলাফল "Yes" হিসেবে রেজলভ হয়, প্রতিটি শেয়ার $1 দেয়। "No" হলে, আপনার "Yes" শেয়ার $0 দেয়। রেজোলিউশনের আগে যেকোনো সময় শেয়ার বিক্রিও করতে পারেন।

"Eli Lilly licenses Peptron’s SmartDepot by October 7?"-এর বর্তমান সম্ভাবনা "Yes"-এর জন্য 13%। মানে Polymarket ক্রাউড বর্তমানে এই ইভেন্টটি ঘটার 13% সম্ভাবনা বিশ্বাস করে। এই অডস প্রকৃত ট্রেডের ভিত্তিতে রিয়েল-টাইমে আপডেট হয়।

"Eli Lilly licenses Peptron’s SmartDepot by October 7?"-এর রেজোলিউশন নিয়ম সঠিকভাবে সংজ্ঞায়িত করে প্রতিটি ফলাফলকে বিজয়ী ঘোষণা করতে কী ঘটতে হবে — ফলাফল নির্ধারণে ব্যবহৃত অফিসিয়াল ডেটা সোর্স সহ। আপনি এই পেজের মন্তব্যের উপরে "Rules" সেকশনে সম্পূর্ণ রেজোলিউশন মানদণ্ড রিভিউ করতে পারেন।